Avalo Therapeutics (NASDAQ:AVTX) Insider Sells 679 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of Avalo Therapeutics stock in a transaction on Friday, August 28th. The stock was sold at an average price of $20.00, for a total value of $13,580.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $1,035,520. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00.
• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX traded down $0.39 during trading hours on Tuesday, hitting $18.95. The stock had a trading volume of 606,643 shares, compared to its average volume of 1,150,310. Avalo Therapeutics, Inc. has a one year low of $8.65 and a one year high of $24.27. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -4.34 and a beta of 0.80. The business’s 50 day moving average is $19.03 and its 200-day moving average is $16.82.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, sell-side analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AVTX has been the topic of a number of research reports. Guggenheim set a $48.00 price target on Avalo Therapeutics and gave the company a “buy” rating in a report on Friday, August 7th. Bank of America started coverage on shares of Avalo Therapeutics in a research note on Friday, June 12th. They issued a “buy” rating and a $35.00 target price for the company. HC Wainwright lowered their price target on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Citizens Jmp dropped their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Finally, Wedbush cut their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AVTX. UBS Group AG boosted its position in shares of Avalo Therapeutics by 956.9% in the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after acquiring an additional 432,608 shares during the period. Nan Fung Trinity HK Ltd. bought a new position in Avalo Therapeutics during the fourth quarter worth about $3,432,000. Sei Investments Co. bought a new position in Avalo Therapeutics during the first quarter worth about $849,000. Renaissance Technologies LLC raised its stake in Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after purchasing an additional 101,814 shares in the last quarter. Finally, Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after purchasing an additional 510,540 shares in the last quarter. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.